Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 29 June 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.54 per Ordinary Share, and notional ADSs at a price of $45.37 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2012 to 30 June 2012:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
|
|
|
Sir Christopher Gent |
2,321.183 |
|
|
|
|
Professor Sir Roy Anderson |
580.296 |
|
|
|
|
Dr Stephanie Burns |
|
454.703 |
|
|
|
Stacey Cartwright |
322.387 |
|
|
|
|
Lawrence Culp |
|
909.406 |
|
|
|
Sir Crispin Davis |
2,149.243 |
|
|
|
|
Judy Lewent |
|
227.352 |
|
|
|
Sir Deryck Maughan |
|
909.406 |
|
|
|
Dr Daniel Podolsky |
|
876.927 |
|
|
|
Tom de Swaan |
795.220 |
|
|
|
|
Sir Robert Wilson |
580.296 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 2 July 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 July 2012